<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "5: principally from research", fill: "#1e4d2b"},
{source: "5: principally from research", target: "5: development", fill: "#1e4d2b"},
{source: "5: development", target: "5: product candidates", fill: "#1e4d2b"},
{source: "5: product candidates", target: "5: establishment", fill: "#1e4d2b"},
{source: "5: establishment", target: "5: facilities", fill: "#1e4d2b"},
{source: "5: facilities", target: "5: administrative costs", fill: "#1e4d2b"},
{source: "5: administrative costs", target: "5: operations", fill: "#1e4d2b"},
{source: "5: principally from research", target: "6: foreseeable future as", fill: "#fffafa"},
{source: "6: foreseeable future as", target: "6: development costs", fill: "#fffafa"},
{source: "6: development costs", target: "6: associated with conducting preclinical testing", fill: "#fffafa"},
{source: "6: associated with conducting preclinical testing", target: "6: clinical trials", fill: "#fffafa"},
{source: "6: clinical trials", target: "6: regulatory compliance activities", fill: "#fffafa"},
{source: "6: foreseeable future as", target: "38: However ", fill: "#c0c0c0"},
{source: "38: However ", target: "38: manufacture", fill: "#c0c0c0"},
{source: "38: manufacture", target: "38: formulations", fill: "#c0c0c0"},
{source: "38: However ", target: "242: beneficially", fill: "#414833"},
{source: "242: beneficially", target: "242: outstanding common stock", fill: "#414833"},
{source: "242: beneficially", target: "247: common stock", fill: "#f984ef"},
{source: "247: common stock", target: "247: perception", fill: "#f984ef"},
{source: "247: perception", target: "247: could depress", fill: "#f984ef"},
{source: "247: common stock", target: "START_HERE", fill: "#f984ef"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Application Software</td>
    </tr>
    <tr>
      <td>Food Distributors</td>
    </tr>
    <tr>
      <td>Trading Companies and Distributors</td>
    </tr>
    <tr>
      <td>Construction and Engineering</td>
    </tr>
    <tr>
      <td>Construction Materials</td>
    </tr>
    <tr>
      <td>Construction and Farm Machinery and Heavy Trucks</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Biotechnology</td>
    </tr>
    <tr>
      <td>Fertilizers and Agricultural Chemicals</td>
    </tr>
    <tr>
      <td>Diversified Chemicals</td>
    </tr>
    <tr>
      <td>Specialty Chemicals</td>
    </tr>
    <tr>
      <td>Environmental Services</td>
    </tr>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Material Aid</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
    <tr>
      <td>Ease</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Seize</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Adjust</td>
    </tr>
    <tr>
      <td>Grant</td>
    </tr>
    <tr>
      <td>Rally support</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Reward</td>
    </tr>
    <tr>
      <td>Pessimistic comment</td>
    </tr>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arrested_Development">Arrested Development</a></td>
      <td>Arrested Development is an American television sitcom created by Mitchell Hurwitz, which originally aired on Fox for three seasons from  2003 to 2006, followed by a two-season revival on Netflix from 2013 to 2019. The show follows the Bluths, a formerly wealthy dysfunctional family.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sustainable_development">Sustainable development</a></td>
      <td>Sustainable development is an organizing principle for meeting human development goals while also sustaining the ability of natural systems to provide the natural resources and ecosystem services on which the economy and society depend. The desired result is a state of society where living conditions and resources are used to continue to meet human needs without undermining the integrity and stability of the natural system.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development/For!">Development/For!</a></td>
      <td>Development/For! (Latvian: Attīstībai/Par!, AP!) is a liberal political alliance in Latvia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Research_and_development">Research and development</a></td>
      <td>Research and development (R&amp;D or R+D), known in Europe as research and technological development (RTD), is the set of innovative activities undertaken by corporations or governments in developing new services or products, and improving existing ones. Research and development constitutes the first stage of development of a potential new service or the production process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Software_development">Software development</a></td>
      <td>Software development is the process of conceiving, specifying, designing, programming, documenting, testing, and bug fixing involved in creating and maintaining applications, frameworks, or other software components. Software development involves writing and maintaining the source code, but in a broader sense, it includes all processes from the conception of the desired software through to the final manifestation of the software, typically in a planned and structured process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Child_development">Child development</a></td>
      <td>Child development involves the biological, psychological and emotional changes that occur in human beings between birth and the conclusion of adolescence. Childhood is divided into 3 stages of life which include early childhood, middle childhood, late childhood ( preadolescence).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Personal_development">Personal development</a></td>
      <td>Personal development or self improvement consists of activities that develop a person's capabilities and potential, build human capital, facilitate employability, and enhance quality of life and the realization of dreams and aspirations. Personal development may take place over the course of an individual's entire lifespan and is not limited to one stage of a person's life.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Halozyme">Halozyme</a></td>
      <td>Halozyme Therapeutics is an American biotechnology company that develops novel oncology therapies designed to target the tumor microenvironment and licenses a novel drug delivery technology through corporate partnerships.\nThe company was founded in 1998 and went public in 2004.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/MannKind_Corporation">MannKind Corporation</a></td>
      <td>MannKind Corporation is a biopharmaceutical company focusing on the discovery, development, and commercialization of therapeutic products for diseases such as diabetes and pulmonary arterial hypertension. Based in Danbury, Connecticut, the company was founded in February 1991.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Aerie_Pharmaceuticals">Aerie Pharmaceuticals</a></td>
      <td>Aerie Pharmaceuticals Inc. (Nasdaq: AERI) is a publicly traded, clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/MediGene">MediGene</a></td>
      <td>Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. Medigene is working on the development of immunotherapies to enhance T cell activity against solid cancers.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bavarian_Nordic">Bavarian Nordic</a></td>
      <td>Bavarian Nordic A/S is a fully integrated biotechnology company focused on the development, manufacturing and commercialization of vaccines for infectious diseases and cancer immunotherapies. The company is headquartered in Hellerup, Denmark, with a manufacturing facility in Kvistgård, and an additional site in Hørsholm.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Medicago_Inc.">Medicago Inc.</a></td>
      <td>Medicago Inc. is a privately-owned Canadian biotechnology company focused on the discovery, development, and commercialization of virus-like particles using plants as "bioreactors" to produce proteins as candidate vaccines and medications.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Takeda_Oncology">Takeda Oncology</a></td>
      <td>Takeda Oncology (originally Millennium Pharmaceuticals) is a biopharmaceutical company based in Cambridge, Massachusetts. It is a fully owned subsidiary of Takeda Pharmaceutical.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Preregistration_(science)">Preregistration (science)</a></td>
      <td>Preregistration is the practice of registering the hypotheses, methods, and/or analyses of a scientific study before it is conducted. This can include analyzing primary data or secondary data.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clinical_trial">Clinical trial</a></td>
      <td>Clinical trials are experiments or observations done in clinical research. Such prospective biomedical or behavioral research studies on human participants are designed to answer specific questions about biomedical or behavioral interventions, including new treatments (such as novel vaccines, drugs, dietary choices, dietary supplements, and medical devices) and known interventions that warrant further study and comparison.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Phases_of_clinical_research">Phases of clinical research</a></td>
      <td>The phases of clinical research are the stages in which scientists conduct experiments with a health intervention to obtain sufficient evidence for a process considered effective as a medical treatment. For drug development, the clinical phases start with testing for safety in a few human subjects, then expand to many study participants (potentially tens of thousands) to determine if the treatment is effective.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/ClinicalTrials.gov">ClinicalTrials.gov</a></td>
      <td>ClinicalTrials.gov is a registry of clinical trials. It is run by the United States National Library of Medicine (NLM) at the National Institutes of Health, and is the largest clinical trials database, holding registrations from over 329,000 trials from 209 countries.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Adaptive_clinical_trial">Adaptive clinical trial</a></td>
      <td>An adaptive clinical trial is a dynamic clinical trial that evaluates a medical device or treatment by observing participant outcomes (and possibly other measures, such as side-effects) on a prescribed schedule, and, uniquely, modifying parameters of the trial protocol in accord with those observations. This is in contrast to traditional randomized clinical trials (RCTs) that are static in their protocol and do not modify any parameters until the trial is completed.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Randomized_controlled_trial">Randomized controlled trial</a></td>
      <td>A randomized controlled trial (or randomized control trial; RCT) is a form of scientific experiment used to control factors not under direct experimental control. Examples of RCTs are clinical trials that compare the effects of drugs, surgical techniques, medical devices, diagnostic procedures or other medical treatments.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pragmatic_clinical_trial">Pragmatic clinical trial</a></td>
      <td>A pragmatic clinical trial (PCT), sometimes called a practical clinical trial (PCT), is a clinical trial that focuses on correlation between treatments and outcomes in real-world health system practice rather than focusing on proving causative explanations for outcomes, which requires extensive deconfounding with inclusion and exclusion criteria so strict that they risk rendering the trial results irrelevant to much of real-world practice.\n\n\n== Examples ==\nA typical example is that an anti-diabetic medication in the real world will often be used in people with (latent or apparent) diabetes-induced kidney problems, but if a study of its efficacy and safety excluded some subsets of people with kidney problems (to escape confounding), the study's results may not reflect well what will actually happen in broad practice.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clinical_trials_in_India">Clinical trials in India</a></td>
      <td>Clinical trials in India refers to clinical research in India in which researchers test drugs and other treatments on research participants. NDCTR 2019 and section 3.7.1 to 3.7.3 of ICMR guidelines requires that all researchers conducting a clinical trial must publicly document it in the Clinical Trials Registry - India.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Monitoring_in_clinical_trials">Monitoring in clinical trials</a></td>
      <td>Clinical monitoring is the oversight and administrative efforts that monitor a participant's health and efficacy of the treatment during a clinical trial. Both independent and government-run grant-funding agencies, such as the National Institutes of Health (NIH) and the World Health Organization (WHO), require data and safety monitoring protocols for Phase I and II clinical trials conforming to their standards.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clinical_trials_on_Ayurveda">Clinical trials on Ayurveda</a></td>
      <td>Clinical trials on Ayurveda refers to any clinical trials done on Ayurvedic treatment. Ayurveda is a traditional medicine system in India and like other cultural medical practices includes both conventional medicine and also complementary and alternative medicine.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing">Manufacturing</a></td>
      <td>Manufacturing is the creation or production of goods with the help of equipment, labor, machines, tools, and chemical or biological processing or formulation. It is the essence of secondary sector of the economy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Automotive_industry">Automotive industry</a></td>
      <td>The automotive industry comprises a wide range of companies and organizations involved in the design, development, manufacturing, marketing, and selling of motor vehicles. It is one of the world's largest industries by revenue (from 16 % such as in France up to 40 % to countries like Slovakia).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Common_stock">Common stock</a></td>
      <td>Common stock is a form of corporate equity ownership, a type of security. The terms voting share and ordinary share are also used frequently outside of the United States.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Consolidation_(business)">Consolidation (business)</a></td>
      <td>In business, consolidation or amalgamation is the merger and acquisition of many smaller companies into a few much larger ones. In the context of financial accounting, consolidation refers to the aggregation of financial statements of a group company as consolidated financial statements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Treasury_stock">Treasury stock</a></td>
      <td>A treasury stock or reacquired stock is stock which is bought back by the issuing company, reducing the amount of outstanding stock on the open market ("open market" including insiders' holdings). \nStock repurchases are used as a tax efficient method to put cash into shareholders' hands, rather than paying dividends, in jurisdictions that treat capital gains more favorably.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Common_stock_dividend">Common stock dividend</a></td>
      <td>A common stock dividend is the dividend paid to common stock owners from the profits of the company.  Like other dividends, the payout is in the form of either cash or stock.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Matthiola_incana">Matthiola incana</a></td>
      <td>Matthiola incana is a species of flowering plant in the cabbage family Brassicaceae. Common names include Brompton stock, common stock, hoary stock, ten-week stock, and gilly-flower.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/New_York_Stock_Exchange">New York Stock Exchange</a></td>
      <td>The New York Stock Exchange (NYSE, nicknamed "The Big Board") is an American stock exchange in the Financial District of Lower Manhattan in New York City. It is by far the world's largest stock exchange by market capitalization of its listed companies at US$30.1 trillion as of February 2018.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Convertible_bond">Convertible bond</a></td>
      <td>In finance, a convertible bond or  convertible note or convertible debt (or a convertible debenture if it has a maturity of greater than 10 years) is a type of bond that the holder can convert into a specified number of shares of common stock in the issuing company or cash of equal value.  It is a hybrid security with debt- and equity-like features.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>ADVANCIS PHARMACEUTICAL CORP      Item 1A  Risk Factors       There are a number of <font color="blue">important factors</font> that could cause our actual results     to  <font color="blue">differ <font color="blue">materially</font> from</font> those that are indicated by forward-looking     statements</td>
    </tr>
    <tr>
      <td>Those factors include, <font color="blue">without limitation</font>, those listed below     and <font color="blue">elsewhere herein</font></td>
    </tr>
    <tr>
      <td><font color="blue">Risks Related </font>to our Business       We expect to <font color="blue">incur losses</font> for the <font color="blue">foreseeable future</font> and <font color="blue">may never become</font>     profitable</td>
    </tr>
    <tr>
      <td>From the date we began <font color="blue">operations</font> <font color="blue">in January </font>2000 through <font color="blue">December </font>31, 2005,     we have incurred operating losses of approximately dlra111dtta4 million, including     operating losses of approximately dlra34dtta0 million for the fiscal year ended     <font color="blue">December </font>31, 2005, dlra34dtta7 million for the fiscal year ended <font color="blue">December </font>31,     2004, and dlra19dtta4 million for                                         17       _________________________________________________________________    [68]Table of <font color="blue">Contents       </font>the fiscal year ended <font color="blue">December </font>31, 2003</td>
    </tr>
    <tr>
      <td>Our losses to date have resulted     <font color="blue">principally from research</font> and <font color="blue">development</font> costs related to the <font color="blue">development</font>     of our <font color="blue">product <font color="blue">candidates</font></font>, the purchase of equipment and <font color="blue">establishment</font> of     our  <font color="blue">facilities</font>  and  general  and <font color="blue">administrative costs</font> related to our     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We expect to incur substantial losses for the <font color="blue">foreseeable future</font> as a result     of  increases  in  our research and <font color="blue">development</font> costs, including costs     <font color="blue">associated with conducting <font color="blue">preclinical testing</font></font> and <font color="blue"><font color="blue">clinical trial</font>s</font>, and     <font color="blue"><font color="blue">regulatory</font> compliance <font color="blue">activities</font></font></td>
    </tr>
    <tr>
      <td>Our chances for achieving <font color="blue"><font color="blue">profitability</font> will <font color="blue">depend on</font> numerous factors</font>,     including success in:         •  developing and testing <font color="blue">product <font color="blue">candidates</font></font>;         •  achieving <font color="blue">milestones under</font> our <font color="blue">collaboration <font color="blue"><font color="blue">agreement</font>s</font></font>;         •  receiving <font color="blue"><font color="blue"><font color="blue">regulatory</font> approval</font>s</font>;         •  developing <font color="blue"><font color="blue">proprietary</font> <font color="blue">antibiotic products</font></font>;         •  <font color="blue">commercializing</font> our products; and         •  <font color="blue">establishing</font> our <font color="blue">competitive position</font></td>
    </tr>
    <tr>
      <td>Many of these factors will <font color="blue">depend on</font> <font color="blue">circumstances</font> beyond our control</td>
    </tr>
    <tr>
      <td>We     <font color="blue">cannot assure</font> you that we <font color="blue">will ever <font color="blue">become profitable</font></font></td>
    </tr>
    <tr>
      <td><font color="blue">Substantially </font>all of our <font color="blue">product <font color="blue">candidates</font></font> are <font color="blue">based on</font> a finding that     could ultimately prove to be incorrect, or could have limited <font color="blue">applicability</font></td>
    </tr>
    <tr>
      <td><font color="blue">Substantially </font>all of our <font color="blue">product <font color="blue">candidates</font></font> are <font color="blue">based on</font> our finding that     <font color="blue">bacteria exposed</font> to <font color="blue">antibiotics</font> in front-loaded, rapid sequential bursts are     eliminated more <font color="blue">efficiently</font> and <font color="blue"><font color="blue">effective</font>ly than</font> those exposed to presently     <font color="blue">available treatment regimens</font></td>
    </tr>
    <tr>
      <td>Ultimately, our <font color="blue">finding may</font> be incorrect, in     which case our <font color="blue"><font color="blue">pulsatile drugs</font> would</font> not <font color="blue">differ <font color="blue">substantially</font> from competing</font>     drugs and may be inferior to them</td>
    </tr>
    <tr>
      <td>If these products are <font color="blue">substantially</font>     identical or inferior to <font color="blue">products already available</font>, the market for our     <font color="blue"><font color="blue">pulsatile drugs</font> will</font> be reduced or eliminated</td>
    </tr>
    <tr>
      <td>Even if <font color="blue">pulsatile dosing</font> is more <font color="blue"><font color="blue"><font color="blue">effective</font> than</font> <font color="blue">traditional dosing</font></font>, we may     be unable to apply this <font color="blue">finding <font color="blue">successfully</font></font> to a substantial number of     products in the anti-infective market</td>
    </tr>
    <tr>
      <td>Our <font color="blue">preliminary studies indicate</font> that     <font color="blue">pulsatile dosing</font> may not provide superior performance for all types of     <font color="blue">antibiotics</font></td>
    </tr>
    <tr>
      <td>Additionally, we have not conducted any studies with anti-viral     or anti-fungal medications</td>
    </tr>
    <tr>
      <td>If we <font color="blue">cannot apply</font> our <font color="blue">technology</font> to a wide     variety of <font color="blue">antibiotics</font> or other anti-infectives, our <font color="blue">potential market will</font>     be <font color="blue">substantially</font> reduced</td>
    </tr>
    <tr>
      <td>Our delivery <font color="blue">technology</font> may not be <font color="blue">effective</font>, which would prevent us from     <font color="blue">commercializing</font>  products  that  are  more <font color="blue"><font color="blue">effective</font> than</font> those of our     <font color="blue"><font color="blue">competitor</font>s</font></td>
    </tr>
    <tr>
      <td>Even  if  we  are correct that <font color="blue">pulsatile dosing</font> is more <font color="blue"><font color="blue">effective</font> than</font>     <font color="blue">traditional dosing</font> of <font color="blue">antibiotics</font>, our delivery <font color="blue">technology</font> must be <font color="blue">effective</font>     in <font color="blue">humans such</font> that the <font color="blue">pulsatile administration</font> of drugs are at levels that     prove <font color="blue">effective</font> in <font color="blue">curing <font color="blue">infections</font></font></td>
    </tr>
    <tr>
      <td>If our PULSYS delivery <font color="blue">technology</font> is     not <font color="blue">effective</font> in delivering <font color="blue">rapid bursts</font> of <font color="blue">antibiotics</font>, or is unable to do     so  at  an  <font color="blue"><font color="blue">appropriate</font> <font color="blue">concentration</font></font> and we are not able to create an     <font color="blue">alternative</font>  delivery  method  for  <font color="blue">pulsatile dosing</font> that proves to be     <font color="blue">effective</font>,  we  will  be  unable to <font color="blue">capitalize on</font> any advantage of our     <font color="blue">discovery</font></td>
    </tr>
    <tr>
      <td>Should this occur, our pulsatile <font color="blue">product <font color="blue">candidates</font></font> may not be     more  <font color="blue">effective</font>  than  those of our <font color="blue"><font color="blue">competitor</font>s</font>, which may decrease or     <font color="blue">eliminate <font color="blue">market <font color="blue">acceptance</font></font></font> of our products</td>
    </tr>
    <tr>
      <td>If a <font color="blue">competitor</font> produces and <font color="blue"><font color="blue">commercialize</font>s</font> an antibiotic that is superior     to our pulsatile <font color="blue">antibiotics</font>, the market for our <font color="blue">potential products</font> would be     reduced or eliminated</td>
    </tr>
    <tr>
      <td>We have devoted a substantial amount of our <font color="blue">research efforts</font> and capital to     the <font color="blue">development</font> of pulsatile <font color="blue">antibiotics</font></td>
    </tr>
    <tr>
      <td><font color="blue">Competitors </font>are developing or have     developed new drugs that <font color="blue">may compete with</font> our pulsatile <font color="blue">antibiotics</font></td>
    </tr>
    <tr>
      <td>For     example, sanofi-aventis recently launched Ketek, a drug that belongs to a     new class of <font color="blue">antibiotics</font> known as ketolides</td>
    </tr>
    <tr>
      <td>This <font color="blue">antibiotic may compete</font>     against our pulsatile <font color="blue">antibiotics</font> in the treatment of <font color="blue">upper respiratory</font>     <font color="blue">tract <font color="blue">infections</font></font></td>
    </tr>
    <tr>
      <td>A number of <font color="blue"><font color="blue">pharmaceutical</font> companies</font> are also developing     new classes of compounds,                                         18       _________________________________________________________________    [69]Table of <font color="blue">Contents       </font>such  as  <font color="blue">oxazolidinones</font>,  that <font color="blue">may also compete against</font> our pulsatile     <font color="blue">antibiotics</font></td>
    </tr>
    <tr>
      <td>In addition, other companies are developing <font color="blue">technologies</font> to     enhance the efficacy of <font color="blue">antibiotics</font> by adding new chemical entities that     inhibit  bacterial  metabolic  function</td>
    </tr>
    <tr>
      <td>If a <font color="blue">competitor</font> produces and     <font color="blue"><font color="blue">commercialize</font>s</font> an antibiotic or method of delivery of <font color="blue">antibiotics</font> that     provides superior safety, <font color="blue">effective</font>ness or other <font color="blue"><font color="blue">significant</font> advantages over</font>     our  pulsatile  <font color="blue">antibiotics</font>, the value of our <font color="blue"><font color="blue">pulsatile drugs</font> would</font> be     <font color="blue">substantially</font> reduced</td>
    </tr>
    <tr>
      <td>As a result, we would need to conduct substantial new     research and <font color="blue">development</font> <font color="blue">activities</font> to establish new product targets, which     would be costly and time consuming</td>
    </tr>
    <tr>
      <td>We have not <font color="blue">commissioned</font> an extensive <font color="blue"><font color="blue">third party</font> patent infringement</font>,     <font color="blue">invalidity</font> and enforceability <font color="blue">investigation</font> on <font color="blue">pulsatile dosing</font> and we are     aware of <font color="blue">one <font color="blue">issued patent</font></font> covering pulsatile delivery</td>
    </tr>
    <tr>
      <td>Our  patents, prior art and <font color="blue">infringement <font color="blue">investigation</font>s</font> were primarily     <font color="blue">conducted by</font> our <font color="blue">senior <font color="blue">management</font></font> and other employees</td>
    </tr>
    <tr>
      <td>Although our patent     counsel  has <font color="blue">consulted with <font color="blue">management</font></font> in <font color="blue">connection with</font> <font color="blue">management</font>’s     <font color="blue"><font color="blue">intellectual property</font> <font color="blue">investigation</font>s</font>, our <font color="blue">patent counsel</font> has not undertaken     an  extensive  <font color="blue">independent analysis</font> to determine whether our pulsatile     <font color="blue">technology</font> infringes upon any <font color="blue"><font color="blue">issued patent</font>s</font> or whether our <font color="blue"><font color="blue">issued patent</font>s</font>     or patent <font color="blue"><font color="blue">application</font>s</font> covering <font color="blue">pulsatile dosing</font> could be invalidated or     rendered unenforceable for any reason</td>
    </tr>
    <tr>
      <td>We are aware of <font color="blue">one <font color="blue">issued patent</font></font>     owned by a <font color="blue">third party</font> that <font color="blue">covers <font color="blue">certain aspects</font></font> of delivering drugs by     use of <font color="blue">two delayed release pulses</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">patent covers</font> a <font color="blue">drug delivery system</font>     employing <font color="blue">two delayed release pulses</font> using two polymers</td>
    </tr>
    <tr>
      <td>The claims made by     this <font color="blue">patent could</font> be argued to <font color="blue">cover <font color="blue">certain aspects</font></font> of our <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>However,  we  believe  that  we will be able to <font color="blue">manufacture</font> and market     <font color="blue">formulations</font> of our <font color="blue">pulsatile products</font> without infringing any valid claims     under this patent</td>
    </tr>
    <tr>
      <td>Any <font color="blue">reformulation</font> of our products, if required, could be     costly and time-consuming and may not be possible</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that     a claim will not be asserted <font color="blue">by such patent holder</font> or any other holder of an     <font color="blue">issued patent</font> that any of our <font color="blue">products infringe</font> their patent or that our     patents are invalid or unenforceable</td>
    </tr>
    <tr>
      <td>We may be exposed to <font color="blue">future <font color="blue">litigation</font></font>     by third parties <font color="blue">based on</font> claims that our products or <font color="blue">activities</font> infringe     the <font color="blue"><font color="blue">intellectual property</font> rights</font> of others</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that, in     the event of <font color="blue">litigation</font>, any claims would be resolved in our favor</td>
    </tr>
    <tr>
      <td>Any     <font color="blue">litigation</font>  or  claims <font color="blue">against us</font>, whether or not valid, may result in     substantial  costs,  could place a <font color="blue">significant</font> strain on our financial     resources, divert the attention of <font color="blue">management</font> and harm our reputation</td>
    </tr>
    <tr>
      <td>In     addition,  intellectual  property <font color="blue">litigation</font> or claims could result in     substantial damages and force us to do one or more of the following:         •  cease selling, incorporating or using any of our products that     <font color="blue">incorporate</font> the <font color="blue">challenged <font color="blue">intellectual property</font></font>;         •  obtain a <font color="blue">license from</font> the holder of the <font color="blue">infringed <font color="blue">intellectual property</font></font>     right, <font color="blue">which license may</font> be costly or may not be <font color="blue">available on reasonable</font>     terms, if at all; or         •  redesign our products, which would be costly and time-consuming and may     not be possible</td>
    </tr>
    <tr>
      <td>We have not <font color="blue">sought patent protection</font> for <font color="blue">certain aspects</font> of our <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>We  have  not  filed  for  patent  <font color="blue">protection with respect</font> to specific     <font color="blue">formulations</font>, materials (including <font color="blue">inactive ingredients</font>) or <font color="blue">manufacturing</font>     process  approaches  that are <font color="blue">incorporate</font>d in our individual pulsatile     <font color="blue">antibiotic products</font>, and we may not <font color="blue">seek such patent coverage</font> in the future</td>
    </tr>
    <tr>
      <td>In producing our pulsatile <font color="blue">antibiotics</font>, we expect to <font color="blue">use general formulation</font>     <font color="blue"><font color="blue">techniques</font> used</font> in the industry that would be <font color="blue">modified by us</font> and which     would, therefore, include know-how and <font color="blue">trade secrets</font> that we have developed</td>
    </tr>
    <tr>
      <td>We cannot be certain that a <font color="blue">patent would issue</font> to <font color="blue">cover such intellectual</font>     property and currently, we <font color="blue">would prefer</font> to keep <font color="blue">such <font color="blue">techniques</font></font> and know-how     as  our  trade  secrets</td>
    </tr>
    <tr>
      <td>In the event a <font color="blue">competitor</font> is able to develop     <font color="blue">technology</font> <font color="blue">substantially</font> similar to ours and patent that approach, we may be     blocked from using certain of our <font color="blue">formulations</font> or <font color="blue">manufacturing</font> process     approaches, which could limit our ability to develop and <font color="blue">commercialize</font>     products</td>
    </tr>
    <tr>
      <td>If we are unable to develop and <font color="blue">successfully</font> <font color="blue">commercialize</font> our product     <font color="blue">candidates</font>, we may never achieve <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>We have not <font color="blue">commercialize</font>d any <font color="blue">pulsatile products</font> or recognized any revenue     from PULSYS <font color="blue">product sales</font></td>
    </tr>
    <tr>
      <td>With the exception of our Amoxicillin PULSYS     product, all of our <font color="blue">pulsatile drugs</font> are in <font color="blue">early stages</font> of <font color="blue">development</font> with     a total of only four pulsatile <font color="blue">product <font color="blue">candidates</font></font> having <font color="blue">been tested</font> in     Phase I/II <font color="blue"><font color="blue">clinical trial</font>s</font>                                         19       _________________________________________________________________    [70]Table of <font color="blue">Contents       </font>to date</td>
    </tr>
    <tr>
      <td>Our Amoxicillin PULSYS product is currently in a <font color="blue">Phase III </font>clinical     trial, however, we <font color="blue">must <font color="blue">successfully</font></font> complete this <font color="blue">Phase III </font><font color="blue">clinical trial</font>     and obtain <font color="blue"><font color="blue">regulatory</font> approval</font> for our <font color="blue">pulsatile products</font> before we are able     to <font color="blue">commercialize</font> <font color="blue">pulsatile products</font> and <font color="blue">generate revenue from</font> their sales</td>
    </tr>
    <tr>
      <td>We  expect  that  we  must conduct <font color="blue">significant</font> <font color="blue">additional</font> research and     <font color="blue">development</font>  <font color="blue">activities</font>  on  our other <font color="blue">pulsatile products</font> <font color="blue">successfully</font>     completing preclinical, Phase I, Phase I/II or Phase II, and <font color="blue">Phase III </font>    <font color="blue"><font color="blue">clinical trial</font>s</font> before we will be able to receive final <font color="blue"><font color="blue">regulatory</font> approval</font>     to <font color="blue">commercialize</font> these <font color="blue">pulsatile products</font></td>
    </tr>
    <tr>
      <td>Even if we succeed in developing     and  <font color="blue">commercializing</font>  one or more of our <font color="blue">pulsatile drugs</font>, we may never     <font color="blue">generate sufficient</font> or <font color="blue">sustainable revenue</font> to <font color="blue">enable us</font> to be profitable</td>
    </tr>
    <tr>
      <td>If we do not <font color="blue"><font color="blue">successfully</font> attract</font> and retain <font color="blue"><font color="blue">collaborative</font> partners</font>, or our     partners do not satisfy their <font color="blue">obligations</font>, we will be unable to develop our     partnered <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>For  certain <font color="blue">product <font color="blue">candidates</font></font>, we intend to <font color="blue"><font color="blue">enter into</font> <font color="blue">collaborative</font></font>     <font color="blue"><font color="blue">arrangement</font>s <font color="blue">with third parties</font></font></td>
    </tr>
    <tr>
      <td>These <font color="blue">collaborations may</font> be <font color="blue">necessary</font> in     order for us to:         •  fund our research and <font color="blue">development</font> <font color="blue">activities</font>;         •  fund <font color="blue">manufacturing</font> by third parties;         •  seek and obtain <font color="blue"><font color="blue"><font color="blue">regulatory</font> approval</font>s</font>; and         •  <font color="blue">successfully</font> <font color="blue">commercialize</font> our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>We  <font color="blue">cannot assure</font> you that we will be able to <font color="blue"><font color="blue">enter into</font> <font color="blue">collaborative</font></font>     <font color="blue"><font color="blue"><font color="blue">agreement</font>s</font> with partners on terms</font> favorable to us, or at all, and any future     <font color="blue"><font color="blue">agreement</font> may expose us</font> to risks that our <font color="blue">partner might fail</font> to fulfill its     <font color="blue">obligations</font> and <font color="blue">delay <font color="blue">commercialization</font></font> of our products</td>
    </tr>
    <tr>
      <td>We also could     <font color="blue">become involved</font> in disputes with partners, which could lead to delays in or     <font color="blue"><font color="blue">termination</font>s</font> of our <font color="blue">development</font> and <font color="blue"><font color="blue">commercialization</font> programs</font> and time     consuming and expensive <font color="blue">litigation</font> or <font color="blue">arbitration</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">inability</font> to enter     <font color="blue">into <font color="blue">additional</font> <font color="blue">collaborative</font> <font color="blue">arrangement</font>s with</font> other partners, or our     failure to maintain such <font color="blue">arrangement</font>s, would limit the number of product     <font color="blue">candidates</font> which we could develop and ultimately, decrease our sources of     any <font color="blue">future revenues</font></td>
    </tr>
    <tr>
      <td>If we <font color="blue">cannot <font color="blue">enter into</font> new licensing <font color="blue">arrangement</font>s</font> or <font color="blue">otherwise gain access</font>     to products, our ability to develop a <font color="blue">diverse product portfolio could</font> be     limited</td>
    </tr>
    <tr>
      <td>A component of our business strategy is in-licensing or acquiring drug     compounds developed by other <font color="blue">pharmaceutical</font> and bio<font color="blue">technology</font> companies or     academic  research  <font color="blue">laboratories</font> that may be marketed and developed or     improved  upon using our novel <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td><font color="blue">Competition </font>for promising     compounds  can  be  intense and currently we have not entered into any     <font color="blue">arrangement</font> to license or acquire any drugs from other companies</td>
    </tr>
    <tr>
      <td>If we are     not able to identify licensing or <font color="blue"><font color="blue">acquisition</font> opportunities</font> or <font color="blue">enter into</font>     <font color="blue">arrangement</font>s on acceptable terms, we will be unable to develop a diverse     portfolio of products</td>
    </tr>
    <tr>
      <td>Any <font color="blue">product candidate</font> that we acquire will require     <font color="blue">additional</font>  research and <font color="blue">development</font> efforts prior to <font color="blue">commercial sale</font>,     including extensive preclinical and/or clinical testing and <font color="blue">approval by</font> the     FDA and <font color="blue">corresponding</font> foreign <font color="blue">regulatory</font> <font color="blue">authorities</font></td>
    </tr>
    <tr>
      <td>All <font color="blue">product <font color="blue">candidates</font></font>     are  prone  to the risks of <font color="blue">failure inherent</font> in <font color="blue">pharmaceutical</font> product     <font color="blue">development</font>, including the <font color="blue">possibility</font> that the <font color="blue">product candidate</font> will not     be safe, non-toxic and <font color="blue">effective</font> or approved by <font color="blue">regulatory</font> <font color="blue">authorities</font></td>
    </tr>
    <tr>
      <td>In     addition, we <font color="blue">cannot assure</font> you that any <font color="blue">approved products</font> that we develop or     acquire  will  be: <font color="blue">manufacture</font>d or produced economically; <font color="blue">successfully</font>     <font color="blue">commercialize</font>d; widely accepted in the marketplace or that we will be able     to recover our <font color="blue">significant</font> <font color="blue">expenditure</font>s in <font color="blue">connection with</font> the <font color="blue">development</font>     or <font color="blue">acquisition</font> of <font color="blue">such products</font></td>
    </tr>
    <tr>
      <td>In addition, proposing, negotiating and     <font color="blue">implementing</font> an economically viable <font color="blue">acquisition</font> is a lengthy and complex     process</td>
    </tr>
    <tr>
      <td>Other  companies, including those with <font color="blue">substantially</font> greater     financial,  sales and marketing resources, <font color="blue">may compete with</font> us for the     <font color="blue">acquisition</font> of <font color="blue">product <font color="blue">candidates</font></font> and <font color="blue">approved products</font></td>
    </tr>
    <tr>
      <td>We may not be able     to acquire the rights to <font color="blue">additional</font> <font color="blue">product <font color="blue">candidates</font></font> and <font color="blue">approved products</font>     on terms that we find acceptable, or at all</td>
    </tr>
    <tr>
      <td>In addition, if we acquire     <font color="blue">product <font color="blue">candidates</font></font> from third parties, we will be <font color="blue">dependent on third parties</font>     to supply <font color="blue">such products</font> to us for sale</td>
    </tr>
    <tr>
      <td>We could be <font color="blue"><font color="blue">materially</font> <font color="blue">adversely</font></font>     <font color="blue">affected by</font> the failure or <font color="blue">inability</font> of <font color="blue">such suppliers</font> to <font color="blue">meet performance</font>,     <font color="blue">re<font color="blue">liability</font></font> and <font color="blue">quality standards</font></td>
    </tr>
    <tr>
      <td>20       _________________________________________________________________    [71]Table of <font color="blue">Contents       </font>Our <font color="blue"><font color="blue">executive officer</font>s</font> and other <font color="blue">key personnel</font> are critical to our business     and our <font color="blue">future success depends on</font> our ability to retain them</td>
    </tr>
    <tr>
      <td>We are <font color="blue">highly dependent on</font> the <font color="blue">principal members</font> of our scientific and     <font color="blue">management</font> teams, especially Edward M Rudnic, our president and chief     <font color="blue">executive officer</font></td>
    </tr>
    <tr>
      <td>In order to pursue our product <font color="blue">development</font>, marketing and     <font color="blue">commercialization</font> plans, we may need to hire <font color="blue">additional</font> personnel with     experience  in clinical testing, <font color="blue">government</font> regulation, <font color="blue">manufacturing</font>,     marketing and business <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>We may not be able to attract and retain     personnel  on  acceptable <font color="blue">terms given</font> the <font color="blue">intense <font color="blue">competition</font></font> for such     personnel among bio<font color="blue">technology</font>, <font color="blue">pharmaceutical</font> and <font color="blue">healthcare companies</font>,     <font color="blue">universities</font> and non-profit <font color="blue">research institutions</font></td>
    </tr>
    <tr>
      <td>We are not aware of any     <font color="blue">present intention</font> of any of our <font color="blue">key personnel</font> to leave our company or to     retire</td>
    </tr>
    <tr>
      <td>However, although we have <font color="blue">employment <font color="blue"><font color="blue">agreement</font>s</font> with</font> our executive     officers, these <font color="blue">employees may terminate</font> their services upon 90 days’ advance     notice</td>
    </tr>
    <tr>
      <td>The loss of any of our <font color="blue">key personnel</font>, or the <font color="blue">inability</font> to attract     and retain qualified personnel, may <font color="blue">significant</font>ly delay or prevent the     <font color="blue">achievement</font> of our research, <font color="blue">development</font> or business <font color="blue">objectives</font> and could     <font color="blue"><font color="blue">materially</font> <font color="blue">adversely</font></font> affect our business, <font color="blue">financial condition</font> and results of     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Although we maintain <font color="blue">key man life insurance on</font> Dr</td>
    </tr>
    <tr>
      <td>Rudnic, such     insurance  may not be sufficient to cover the costs of the loss of his     services and the expense of recruiting and hiring a <font color="blue">new president</font> and chief     <font color="blue">executive officer</font></td>
    </tr>
    <tr>
      <td>Our  ability  to complete <font color="blue"><font color="blue">clinical trial</font>s</font> and ultimately <font color="blue">commercialize</font>     products will be delayed if we are unable to obtain sufficient APIs or     finished <font color="blue">products from</font> certain suppliers</td>
    </tr>
    <tr>
      <td>We obtain active <font color="blue">pharmaceutical</font> ingredients (APIs) and finished products     from certain specialized <font color="blue">manufacture</font>rs for use in <font color="blue">clinical studies</font> that we     intend to conduct without assistance from <font color="blue"><font color="blue">collaborative</font> partners</font></td>
    </tr>
    <tr>
      <td><font color="blue">Although     </font>the <font color="blue">antibiotics</font> and finished products we use in our <font color="blue">clinical studies</font> may be     obtained <font color="blue">from several suppliers</font>, our <font color="blue"><font color="blue">application</font>s</font> for <font color="blue"><font color="blue">regulatory</font> approval</font>     may authorize only one supplier as our source</td>
    </tr>
    <tr>
      <td>In the event an authorized     supplier in an <font color="blue">application</font> for <font color="blue"><font color="blue">regulatory</font> approval</font> loses its <font color="blue">regulatory</font>     status as an acceptable source or <font color="blue">otherwise becomes unable</font> or unwilling to     supply the API or finished products to us at a <font color="blue">commercially</font> reasonable     price, we would need to locate another source</td>
    </tr>
    <tr>
      <td>A change to a supplier not     <font color="blue">previously</font>  approved  in our <font color="blue">application</font> for <font color="blue"><font color="blue">regulatory</font> approval</font> or an     <font color="blue">alteration</font>  in the procedures or <font color="blue">product provided</font> to us by an approved     supplier  may  require  formal  approval  by  the  US Food  and Drug     Administration  (FDA) before we could use the API in the production of     commercial  supplies  for our products or use the finished product for     <font color="blue">commercialization</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">factors could</font> result in delays in conducting or     completing  our <font color="blue"><font color="blue">clinical trial</font>s</font> and delay our ability to <font color="blue">commercialize</font>     products</td>
    </tr>
    <tr>
      <td><font color="blue">Clinical  </font>trials  for our <font color="blue">product <font color="blue">candidates</font></font> may be <font color="blue">delayed due</font> to our     <font color="blue">dependence on third parties</font> for the conduct of such trials</td>
    </tr>
    <tr>
      <td>We have limited experience in conducting and managing <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td>We     rely,  and <font color="blue">will continue</font> to rely, on third parties, including clinical     <font color="blue">research <font color="blue">organizations</font></font> and <font color="blue">outside <font color="blue">consultants</font></font>, to <font color="blue">assist us</font> in managing and     monitoring <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">reliance on</font> these <font color="blue">third parties may</font> result     in delays in <font color="blue">completion</font> of, or the failure to complete, these trials if they     fail to perform their <font color="blue">obligations</font> under our <font color="blue"><font color="blue">agreement</font>s</font></td>
    </tr>
    <tr>
      <td>If <font color="blue"><font color="blue">clinical trial</font>s</font> for our products are <font color="blue">unsuccessful</font> or delayed, we will be     unable to meet our anticipated <font color="blue">development</font> and <font color="blue">commercialization</font> timelines</td>
    </tr>
    <tr>
      <td>We <font color="blue">must demonstrate through <font color="blue">preclinical testing</font></font> and <font color="blue"><font color="blue">clinical trial</font>s</font> that our     <font color="blue">product <font color="blue">candidates</font></font> are safe and <font color="blue">effective</font> for use in humans before we can     obtain <font color="blue"><font color="blue"><font color="blue">regulatory</font> approval</font>s</font> for their <font color="blue">commercial sale</font></td>
    </tr>
    <tr>
      <td>In addition, we will     also need to demonstrate through <font color="blue"><font color="blue">clinical trial</font>s</font> any claims we may wish to     make that our <font color="blue">product <font color="blue">candidates</font></font> are comparable or superior to existing     products</td>
    </tr>
    <tr>
      <td>For <font color="blue"><font color="blue">drug products</font> which</font> are expected to <font color="blue">contain active ingredients</font>     in fixed <font color="blue">combination</font>s that have not been <font color="blue">previously</font> approved by the FDA,     <font color="blue"><font color="blue">clinical studies</font> may also</font> need to be conducted in order to establish the     <font color="blue">contribution</font>  of  each  active  component  to the <font color="blue">effective</font>ness of the     <font color="blue">combination</font> in an <font color="blue"><font color="blue">appropriate</font>ly</font> identified <font color="blue">patient population</font></td>
    </tr>
    <tr>
      <td><font color="blue">Conducting  </font><font color="blue"><font color="blue">clinical trial</font>s</font> is a lengthy, time-consuming and expensive     process</td>
    </tr>
    <tr>
      <td>Currently, we have one Amoxicillin PULSYS product in a <font color="blue">Phase III </font>    <font color="blue">clinical trial</font> for adults and <font color="blue">adolescents</font></td>
    </tr>
    <tr>
      <td>We expect to have results from     the adults and <font color="blue">adolescents</font> trial in the <font color="blue">third quarter</font> of 2006</td>
    </tr>
    <tr>
      <td>For our other     products we have not completed <font color="blue">pre<font color="blue">clinical studies</font></font> and <font color="blue">initial clinical</font>     trials (Phase I, Phase I/II or Phase II) to extrapolate proper dosage for     <font color="blue">Phase III </font>clinical                                         21       _________________________________________________________________    [72]Table of <font color="blue">Contents       </font><font color="blue">efficacy trials</font> in humans</td>
    </tr>
    <tr>
      <td>In the event we incorrectly identify a dosage as     <font color="blue">appropriate</font> for human <font color="blue"><font color="blue">clinical trial</font>s</font>, any results we receive from such     trials  may not properly reflect the optimal efficacy or safety of our     products and may not support approval in the absence of <font color="blue">additional</font> clinical     <font color="blue">trials using</font> a <font color="blue">different dosage</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">commencement</font> and rate of <font color="blue">completion</font> of <font color="blue"><font color="blue">clinical trial</font>s</font> for our products     may be <font color="blue">delayed by</font> many factors, including:         •  lack of <font color="blue">efficacy during</font> the <font color="blue"><font color="blue">clinical trial</font>s</font>;         •  <font color="blue">unforeseen safety issues</font>;         •  <font color="blue">slower than</font> expected rate of <font color="blue">patient recruitment</font>; or         •  <font color="blue">government</font> or <font color="blue">regulatory</font> delays</td>
    </tr>
    <tr>
      <td>The results <font color="blue">from <font color="blue">preclinical testing</font></font> and early <font color="blue"><font color="blue">clinical trial</font>s</font> are often not     predictive of results obtained in later <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td>Although a new     product may show promising results in preclinical and <font color="blue">initial clinical</font>     trials, it may <font color="blue">subsequently</font> prove unfeasible or impossible to generate     sufficient  safety  and  efficacy  data to obtain <font color="blue">necessary</font> <font color="blue">regulatory</font>     approvals</td>
    </tr>
    <tr>
      <td>Data  obtained  from  preclinical and <font color="blue">clinical studies</font> are     susceptible to <font color="blue">varying interpretations</font>, which may delay, limit or prevent     <font color="blue"><font color="blue">regulatory</font> approval</font></td>
    </tr>
    <tr>
      <td>In addition, we may encounter <font color="blue">regulatory</font> delays or     <font color="blue">rejections</font>  as a result of many factors, including results that do not     support our claims, perceived defects in the design of <font color="blue"><font color="blue">clinical trial</font>s</font> and     changes in <font color="blue">regulatory</font> policy during the period of product <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>Our     business, <font color="blue">financial condition</font> and results of <font color="blue">operations</font> may be <font color="blue">materially</font>     <font color="blue">adversely</font> <font color="blue">affected by</font> any delays in, or <font color="blue">termination</font> of, our <font color="blue"><font color="blue">clinical trial</font>s</font>     or a de<font color="blue">termination</font> by the FDA that the results of our trials are inadequate     to justify <font color="blue"><font color="blue">regulatory</font> approval</font></td>
    </tr>
    <tr>
      <td>We will need <font color="blue">additional</font> capital in the future</td>
    </tr>
    <tr>
      <td>If <font color="blue">additional</font> capital is not     available, we may be forced to delay or curtail the <font color="blue">development</font> of our     <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>We anticipate that our <font color="blue">existing capital resources</font> and expected <font color="blue">product sales</font>     will <font color="blue">enable us</font> to maintain our current <font color="blue">operations</font> for at least the next     12 months</td>
    </tr>
    <tr>
      <td>We may need <font color="blue">additional</font> capital to fund our <font color="blue">operations</font> beyond     2006</td>
    </tr>
    <tr>
      <td>Our <font color="blue">requirements</font> for <font color="blue">additional</font> capital could be substantial and will     <font color="blue">depend on</font> many other factors, including:         •  payments received under future <font color="blue">collaborative</font> partner <font color="blue"><font color="blue">agreement</font>s</font>;         •  continued progress of research and <font color="blue">development</font> of our <font color="blue">pulsatile drugs</font>;         •  our ability to acquire or <font color="blue">license drugs from others</font> for use with     PULSYS;         •  <font color="blue">costs associated with protecting</font> our <font color="blue"><font color="blue">intellectual property</font> rights</font>;         •  <font color="blue">development</font> of sales and <font color="blue">marketing capabilities</font>; and         •  <font color="blue">market <font color="blue">acceptance</font></font> of our products</td>
    </tr>
    <tr>
      <td>We have no <font color="blue">significant</font> committed sources of <font color="blue">additional</font> capital</td>
    </tr>
    <tr>
      <td>To the     extent  our  capital resources are insufficient to meet future capital     <font color="blue">requirements</font>,  we  will have to raise <font color="blue">additional</font> funds to continue the     <font color="blue">development</font> of our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that <font color="blue">funds will</font>     be  available  on  favorable  terms, if at all</td>
    </tr>
    <tr>
      <td>To the extent we raise     <font color="blue">additional</font> capital through the sale of securities, the issuance of those     securities could result in dilution to our <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>In addition, if we     obtain <font color="blue">debt financing</font>, a substantial portion of our operating <font color="blue">cash flow may</font>     be dedicated to the payment of principal and <font color="blue">interest on such indebtedness</font>,     <font color="blue">thus limiting funds available</font> for our business <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>If <font color="blue">adequate funds</font>     are  not  available,  we  may be required to curtail <font color="blue">significant</font>ly our     <font color="blue">development</font> and <font color="blue">commercialization</font> <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>We could be forced to pay substantial <font color="blue">damage awards</font> if <font color="blue">product <font color="blue">liability</font></font>     claims that may be <font color="blue">brought <font color="blue">against us</font></font> are successful</td>
    </tr>
    <tr>
      <td>The use of any of our <font color="blue">product <font color="blue">candidates</font></font> in <font color="blue"><font color="blue">clinical trial</font>s</font>, and the sale of     any <font color="blue">approved products</font>, may expose us to <font color="blue">liability</font> claims and financial     losses resulting from the use or sale of our products</td>
    </tr>
    <tr>
      <td>We have obtained     limited <font color="blue">product <font color="blue">liability</font></font> <font color="blue">insurance coverage</font> for our <font color="blue"><font color="blue">clinical trial</font>s</font>, which     we believe is adequate to cover our present                                         22       _________________________________________________________________    [73]Table of <font color="blue">Contents       </font><font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>However, <font color="blue">such <font color="blue">insurance may</font></font> not be adequate to cover any claims     made <font color="blue">against us</font></td>
    </tr>
    <tr>
      <td>In addition, we may not be able to maintain insurance     <font color="blue">coverage at</font> a <font color="blue">reasonable cost</font> or in <font color="blue">sufficient amounts</font> or scope to protect     <font color="blue">us against losses</font></td>
    </tr>
    <tr>
      <td>If our PULSYS products are not <font color="blue">accepted by</font> the market, our revenues and     <font color="blue">profitability</font> will suffer</td>
    </tr>
    <tr>
      <td>Even if we obtain <font color="blue"><font color="blue">regulatory</font> approval</font> to market our PULSYS products, our     products  may  not  gain <font color="blue">market <font color="blue">acceptance</font></font> among physicians, patients,     <font color="blue">healthcare payors</font> and the <font color="blue">medical community</font></td>
    </tr>
    <tr>
      <td>The degree of <font color="blue">market <font color="blue">acceptance</font></font>     of any <font color="blue">pharmaceutical</font> product that we develop will <font color="blue">depend on</font> a number of     factors, including:         •  <font color="blue">demonstration</font> of <font color="blue">clinical efficacy</font> and safety;         •  cost-<font color="blue">effective</font>ness;         •  potential advantages over <font color="blue">alternative</font> therapies;         •  <font color="blue"><font color="blue">reimbursement</font> policies</font> of <font color="blue">government</font> and third-party payors; and         •  <font color="blue">effective</font>ness of our marketing and <font color="blue"><font color="blue">distribution</font> capabilities</font> and the     <font color="blue">effective</font>ness of <font color="blue">such capabilities</font> of our <font color="blue"><font color="blue">collaborative</font> partners</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">product <font color="blue">candidates</font></font>, if <font color="blue">successfully</font> developed, <font color="blue">will compete with</font> a     number  of  products <font color="blue">manufacture</font>d and marketed by major <font color="blue">pharmaceutical</font>     companies, bio<font color="blue">technology</font> companies and <font color="blue">manufacture</font>rs of <font color="blue">generic drugs</font></td>
    </tr>
    <tr>
      <td>Physicians, patients, third-party payors and the <font color="blue">medical community</font>     may not accept and use any <font color="blue">product <font color="blue">candidates</font></font> that we or our <font color="blue">collaborative</font>     partners develop</td>
    </tr>
    <tr>
      <td>To the extent current <font color="blue">antibiotics</font> already <font color="blue">successfully</font>     treat certain <font color="blue">infections</font>, physicians may not be inclined to prescribe our     <font color="blue">pulsatile drugs</font> for the <font color="blue">same indications</font></td>
    </tr>
    <tr>
      <td>If our products do not achieve     <font color="blue">significant</font> <font color="blue">market <font color="blue">acceptance</font></font>, we will not be able to generate <font color="blue">significant</font>     revenues or <font color="blue">become profitable</font></td>
    </tr>
    <tr>
      <td>Because we <font color="blue">depend on</font> a single <font color="blue">manufacture</font>r for Keflex, we may be unable to     obtain <font color="blue">sufficient quantities</font> of these products at <font color="blue">commercially</font> acceptable     rates</td>
    </tr>
    <tr>
      <td>We  obtained  our Keflex <font color="blue">products from</font> <font color="blue">Eli Lilly </font>under a <font color="blue">manufacturing</font>     <font color="blue">agreement</font>  that  expired  in  <font color="blue">December </font> 2005</td>
    </tr>
    <tr>
      <td>We have <font color="blue">transitioned</font> the     <font color="blue">manufacturing</font> of our Keflex products to Ceph International Corporation, a     wholly-owned  subsidiary of Patheon’s MOVA Pharmaceutical Corporation</td>
    </tr>
    <tr>
      <td>Although we believe that the API and finished products for Keflex could be     obtained <font color="blue">from several suppliers</font>, our <font color="blue"><font color="blue">application</font>s</font> for <font color="blue"><font color="blue">regulatory</font> approval</font>     <font color="blue">currently authorize only</font> Ceph as our source</td>
    </tr>
    <tr>
      <td>In the event that Ceph is     unable to supply the products to us at a <font color="blue">commercially</font> reasonable price or     breaches its <font color="blue">agreement</font> with us, or if Ceph loses its <font color="blue">regulatory</font> status as an     acceptable source, we would need to locate another source</td>
    </tr>
    <tr>
      <td>A change to a     supplier not <font color="blue">previously</font> approved or an <font color="blue">alteration</font> in the procedures or     <font color="blue">product provided</font> to us by an <font color="blue">approved supplier may</font> require <font color="blue">formal approval</font>     by the FDA before the <font color="blue">product could</font> be sold</td>
    </tr>
    <tr>
      <td>These <font color="blue">factors could</font> limit our     ability to sell Keflex and would <font color="blue"><font color="blue">materially</font> <font color="blue">adversely</font></font> affect our revenues</td>
    </tr>
    <tr>
      <td>We  rely  upon  a  limited  number  of  <font color="blue">pharmaceutical</font> <font color="blue">wholesalers</font> and     <font color="blue">distributors</font>, which could impact our ability to sell our Keflex product</td>
    </tr>
    <tr>
      <td>We rely largely upon specialty <font color="blue">pharmaceutical</font> <font color="blue">distributors</font> and <font color="blue">wholesalers</font>     to  deliver  Keflex to end users, including physicians, hospitals, and     pharmacies</td>
    </tr>
    <tr>
      <td>There  can  be  no  assurance that these <font color="blue">distributors</font> and     <font color="blue">wholesalers</font> will adequately fulfill the <font color="blue">market demand</font> for Keflex, nor can     there be any guarantee that these <font color="blue">service providers will remain solvent</font></td>
    </tr>
    <tr>
      <td>Given the high <font color="blue">concentration</font> of sales to certain <font color="blue">pharmaceutical</font> <font color="blue">distributors</font>     and <font color="blue">wholesalers</font>, we could experience a <font color="blue">significant</font> loss if one of our top     customers were to declare <font color="blue">bankruptcy</font> or otherwise become unable to pay its     <font color="blue">obligations</font> to us</td>
    </tr>
    <tr>
      <td>We  are  subject  to  <font color="blue">therapeutic</font>  equivalent  <font color="blue">substitution</font>,  <font color="blue">Medicaid     </font><font color="blue">reimbursement</font> and price reporting</td>
    </tr>
    <tr>
      <td>The  cost  of  <font color="blue">pharmaceutical</font>  products  continues  to be a subject of     <font color="blue">investigation</font> and action by <font color="blue">government</font>al agencies, <font color="blue">legislative</font> bodies and     <font color="blue">private <font color="blue">organizations</font></font> in the US and other countries</td>
    </tr>
    <tr>
      <td>In the US, most     states  have  <font color="blue">enacted <font color="blue">legislation</font></font> requiring or permitting a dispensing     <font color="blue">pharmacist</font> to substitute a <font color="blue">generic equivalent</font> to the                                         23       _________________________________________________________________    [74]Table of <font color="blue">Contents       </font><font color="blue">prescribed drug</font></td>
    </tr>
    <tr>
      <td>Federal <font color="blue">legislation</font> requires <font color="blue">pharmaceutical</font> <font color="blue">manufacture</font>rs     to pay to state Medicaid <font color="blue">agencies prescribed rebates on drugs</font> to <font color="blue">enable them</font>     to be eligible for <font color="blue">reimbursement</font> under Medicaid programs</td>
    </tr>
    <tr>
      <td>Federal and state     <font color="blue">government</font>s  continue to pursue efforts to reduce spending in <font color="blue">Medicaid     </font>programs, including <font color="blue">restrictions on amounts agencies will reimburse</font> for     <font color="blue">certain products</font></td>
    </tr>
    <tr>
      <td>In addition, some states are <font color="blue">seeking rebates</font> in excess of     the amounts required <font color="blue">by federal law</font>, and there are <font color="blue">federal <font color="blue">legislative</font></font>     proposals to <font color="blue">expand current</font> Medicaid rebates</td>
    </tr>
    <tr>
      <td>We <font color="blue">also must give discounts</font> or     <font color="blue">rebates on purchases</font> or <font color="blue">reimbursement</font>s of Keflex by certain other federal     and state agencies and programs</td>
    </tr>
    <tr>
      <td>Our ability to <font color="blue">earn sufficient returns on</font>     Keflex depends, in part, on the <font color="blue">availability</font> of <font color="blue">reimbursement</font>s from third     party payers, such as health insurers, <font color="blue">government</font>al health administration     <font color="blue">authorities</font> and other <font color="blue">organizations</font> and the amount of <font color="blue">rebates payable under</font>     Medicaid programs</td>
    </tr>
    <tr>
      <td>Our  ability to conduct <font color="blue"><font color="blue">clinical trial</font>s</font> will be impaired if we fail to     qualify our clinical supply <font color="blue">manufacturing</font> <font color="blue">facility</font> and we are unable to     maintain <font color="blue">relationships with</font> current clinical supply <font color="blue">manufacture</font>rs or enter     into <font color="blue">relationships with</font> new <font color="blue">manufacture</font>rs</td>
    </tr>
    <tr>
      <td>We <font color="blue">currently rely on several contractors</font> to <font color="blue">manufacture</font> product samples for     our  clinical  studies</td>
    </tr>
    <tr>
      <td>In  the  fourth quarter of 2003, we completed     <font color="blue">construction</font> of a <font color="blue">manufacturing</font> <font color="blue">facility</font> for production of <font color="blue">clinical supplies</font>     sufficient  for use through our Phase II and, in some cases, <font color="blue">Phase III </font>    <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td>We expect this <font color="blue">facility</font> to be qualified and operational in     the future</td>
    </tr>
    <tr>
      <td>We have no experience qualifying <font color="blue">manufacturing</font> <font color="blue">facilities</font> and we     may  not  be  able  to qualify the <font color="blue">facility</font></td>
    </tr>
    <tr>
      <td>If we are <font color="blue">unsuccessful</font> in     qualifying  our  own  <font color="blue">manufacturing</font>  <font color="blue">facility</font> and fail to maintain our     <font color="blue">relationships with</font> our current clinical supply <font color="blue">manufacture</font>rs or <font color="blue">enter into</font>     <font color="blue">relationships with</font> new <font color="blue">manufacture</font>rs, we will be unable to conduct our     <font color="blue"><font color="blue">clinical trial</font>s</font> <font color="blue">effective</font>ly</td>
    </tr>
    <tr>
      <td>We intend to <font color="blue">rely on third parties</font> to <font color="blue">manufacture</font> products that we intend to     <font color="blue">sell through</font> our own <font color="blue">commercialization</font> and <font color="blue">sales efforts</font></td>
    </tr>
    <tr>
      <td>We believe that     there are a variety of <font color="blue">manufacture</font>rs that we may retain to produce these     products</td>
    </tr>
    <tr>
      <td>However, once we retain a <font color="blue">manufacturing</font> source, if we are unable     to  maintain our relationship with such <font color="blue">manufacture</font>r, qualifying a new     <font color="blue">manufacturing</font> source will be time consuming and expensive, and may cause     delays in the <font color="blue">development</font> of our products</td>
    </tr>
    <tr>
      <td>If we fail to establish sales, marketing, and <font color="blue"><font color="blue">distribution</font> capabilities</font>, or     fail to <font color="blue">enter into</font> <font color="blue"><font color="blue">arrangement</font>s <font color="blue">with third parties</font></font>, we will not be able to     <font color="blue">commercialize</font> our products</td>
    </tr>
    <tr>
      <td>We have limited sales, marketing, and <font color="blue"><font color="blue">distribution</font> capabilities</font></td>
    </tr>
    <tr>
      <td>In order to     <font color="blue">commercialize</font> any <font color="blue">product <font color="blue">candidates</font></font> that receive final <font color="blue"><font color="blue">regulatory</font> approval</font>,     we <font color="blue">must considerably expand</font> our <font color="blue">commercial capabilities</font> or make <font color="blue">arrangement</font>s     <font color="blue">with third parties</font> to perform these services for us</td>
    </tr>
    <tr>
      <td>In order to market any     of  our  product  <font color="blue">candidates</font> directly, we <font color="blue">must considerably expand</font> our     <font color="blue">commercial infrastructure</font>, including <font color="blue">distribution</font>, marketing, and sales     personnel</td>
    </tr>
    <tr>
      <td>The  expansion  or <font color="blue">contracting</font> of a sales and <font color="blue">distribution</font>     <font color="blue">infrastructure would</font> require substantial resources, which may divert the     attention  of  our  <font color="blue">management</font> and <font color="blue">key personnel</font> and defer our product     <font color="blue">development</font> efforts</td>
    </tr>
    <tr>
      <td>To the extent that we <font color="blue">enter into</font> sales and marketing     <font color="blue">arrangement</font>s with other companies, our revenues will <font color="blue">depend on</font> the efforts     of others</td>
    </tr>
    <tr>
      <td>These <font color="blue">efforts may</font> not be successful</td>
    </tr>
    <tr>
      <td>If we fail to <font color="blue">expand sales</font>,     marketing and <font color="blue"><font color="blue">distribution</font> capabilities</font>, or fail to <font color="blue">enter into</font> <font color="blue">arrangement</font>s     <font color="blue">with third parties</font>, we will experience delays in <font color="blue">product sales</font> and incur     <font color="blue">increased costs</font></td>
    </tr>
    <tr>
      <td><font color="blue">Risks Related </font>to our Industry       Any  <font color="blue">inability</font>  to  protect  our  <font color="blue"><font color="blue">intellectual property</font> could harm</font> our     <font color="blue">competitive position</font></td>
    </tr>
    <tr>
      <td>Our  success  will depend in part on our ability to obtain patents and     maintain  adequate  protection  of other <font color="blue">intellectual property</font> for our     <font color="blue">technologies</font> and products in the US and other countries</td>
    </tr>
    <tr>
      <td>If we do not     <font color="blue">adequately protect</font> our <font color="blue">intellectual property</font>, <font color="blue"><font color="blue">competitor</font>s</font> may be able to use     our <font color="blue">technologies</font> and erode or negate our <font color="blue">competitive advantage</font></td>
    </tr>
    <tr>
      <td>Further, the     laws of some foreign countries do not protect our <font color="blue">proprietary</font> rights to the     same  extent as the laws of the US, and we may encounter <font color="blue">significant</font>     problems in protecting our <font color="blue">proprietary</font> rights in these foreign countries</td>
    </tr>
    <tr>
      <td>The  patent  positions  of <font color="blue">pharmaceutical</font> and bio<font color="blue">technology</font> companies,     including our patent positions, involve complex legal and factual questions     and,  therefore,  validity and <font color="blue">enforceability cannot</font> be <font color="blue">predicted with</font>     <font color="blue">certainty</font></td>
    </tr>
    <tr>
      <td>Patents may be challenged, deemed unenforceable, invalidated or     <font color="blue">circumvented</font></td>
    </tr>
    <tr>
      <td>We will be able to protect our                                         24       _________________________________________________________________    [75]Table of <font color="blue">Contents       </font><font color="blue">proprietary</font> rights from unauthorized use by third parties only to the extent     that  we cover our <font color="blue">proprietary</font> <font color="blue">technologies</font> with valid and enforceable     patents or we <font color="blue">effective</font>ly maintain such <font color="blue">proprietary</font> <font color="blue">technologies</font> as trade     secrets</td>
    </tr>
    <tr>
      <td>We will apply for <font color="blue">patents covering both</font> our <font color="blue">technologies</font> and     <font color="blue">product <font color="blue">candidates</font></font> as we deem <font color="blue">appropriate</font></td>
    </tr>
    <tr>
      <td>We may fail to apply for patents     on important <font color="blue">technologies</font> or products in a <font color="blue">timely fashion</font>, or at all, and in     any event, the <font color="blue"><font color="blue">application</font>s</font> we do file may be challenged and may not result     in <font color="blue"><font color="blue">issued patent</font>s</font></td>
    </tr>
    <tr>
      <td>Any <font color="blue">future patents</font> we obtain may not be <font color="blue">sufficiently</font>     broad to <font color="blue">prevent others from practicing</font> our <font color="blue">technologies</font> or from developing     <font color="blue"><font color="blue">competing product</font>s</font></td>
    </tr>
    <tr>
      <td>Furthermore, <font color="blue">others may independently</font> develop similar or     <font color="blue">alternative</font> <font color="blue">technologies</font> or <font color="blue">design around</font> our patented <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>In     addition, if challenged, our <font color="blue">patents may</font> be declared invalid</td>
    </tr>
    <tr>
      <td>Even if valid,     our <font color="blue">patents may</font> fail to <font color="blue">provide us with</font> any <font color="blue">competitive advantage</font>s</td>
    </tr>
    <tr>
      <td>We rely upon <font color="blue">trade secrets</font> protection for our <font color="blue">confidential</font> and <font color="blue">proprietary</font>     information</td>
    </tr>
    <tr>
      <td>We have <font color="blue">taken measures</font> to protect our <font color="blue">proprietary</font> information;     however, these <font color="blue">measures may</font> not <font color="blue">provide adequate protection</font></td>
    </tr>
    <tr>
      <td>We seek to     protect  our  <font color="blue">proprietary</font> information by entering into <font color="blue">confidential</font>ity     <font color="blue"><font color="blue">agreement</font>s</font> with employees, collaborators and <font color="blue">consultants</font></td>
    </tr>
    <tr>
      <td>Nevertheless,     employees, collaborators or <font color="blue">consultants</font> may still disclose our <font color="blue">proprietary</font>     information,  and we may not be able to <font color="blue">meaningfully protect</font> our trade     secrets</td>
    </tr>
    <tr>
      <td>In  addition, <font color="blue">others may independently</font> develop <font color="blue">substantially</font>     equivalent <font color="blue">proprietary</font> information or <font color="blue">techniques</font> or <font color="blue">otherwise gain access</font> to     our <font color="blue">trade secrets</font></td>
    </tr>
    <tr>
      <td>If we do not compete <font color="blue">successfully</font> in the <font color="blue">development</font> and <font color="blue">commercialization</font>     of products and keep <font color="blue">pace with <font color="blue">rapid technological</font></font> change, we will be unable     to capture and sustain a <font color="blue">meaningful market position</font></td>
    </tr>
    <tr>
      <td>The bio<font color="blue">technology</font> and <font color="blue">pharmaceutical</font> industries are <font color="blue">highly competitive</font> and     subject to <font color="blue">significant</font> and <font color="blue">rapid technological</font> change</td>
    </tr>
    <tr>
      <td>While we are not     aware  of any company using <font color="blue">rapid bursts</font> of <font color="blue">antibiotics</font> as a treatment     method, there are <font color="blue">numerous companies actively</font> engaged in the research and     <font color="blue">development</font> of anti-infectives</td>
    </tr>
    <tr>
      <td>Our main <font color="blue"><font color="blue">competitor</font>s</font> are:         •  Large <font color="blue"><font color="blue">pharmaceutical</font> companies</font>, such as Pfizer, GlaxoSmithKline, Wyeth,     Bristol-Myers Squibb, Merck, Johnson &amp; Johnson, Roche, Schering-Plough,     Novartis, sanofi-aventis, Abbott Laboratories, AstraZeneca, and Bayer, that     may develop <font color="blue">new drug compounds</font> that render our <font color="blue">drugs obsolete</font> or     <font color="blue">noncompetitive</font></td>
    </tr>
    <tr>
      <td>•  Smaller <font color="blue">pharmaceutical</font> and bio<font color="blue">technology</font> companies and specialty     <font color="blue"><font color="blue">pharmaceutical</font> companies</font> engaged in <font color="blue">focused research</font> and <font color="blue">development</font> of     anti-infective drugs, such as Trimeris, Vertex, Gilead Sciences, Cubist,     Basilea, Intermune, King, and others</td>
    </tr>
    <tr>
      <td>•  Drug delivery companies, such as Johnson &amp; Johnson’s Alza division,     Biovail and SkyePharma, which may develop a <font color="blue">dosing regimen</font> that is more     <font color="blue"><font color="blue">effective</font> than</font> <font color="blue">pulsatile dosing</font></td>
    </tr>
    <tr>
      <td>•  Generic drug companies, such as Teva, Ranbaxy, IVAX, Sandoz and Stada,     which produce low-cost versions of <font color="blue">antibiotics</font> that may contain the same     active <font color="blue">pharmaceutical</font> ingredients as our PULSYS <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>Many of these <font color="blue"><font color="blue">competitor</font>s</font>, either alone or together with their <font color="blue">collaborative</font>     partners, have <font color="blue">substantially</font> greater financial resources and larger research     and <font color="blue">development</font> staffs than we do</td>
    </tr>
    <tr>
      <td>In addition, many of these <font color="blue"><font color="blue">competitor</font>s</font>,     either  alone  or  together  with  their  <font color="blue"><font color="blue">collaborative</font> partners</font>, have     <font color="blue">significant</font>ly greater experience than we do in:         •  developing products;         •  undertaking <font color="blue">preclinical testing</font> and human <font color="blue"><font color="blue">clinical trial</font>s</font>;         •  obtaining approvals of <font color="blue">products from</font> the FDA and other <font color="blue">regulatory</font>     agencies; and         •  <font color="blue">manufacturing</font> and <font color="blue">marketing products</font></td>
    </tr>
    <tr>
      <td><font color="blue">Developments </font><font color="blue">by others may</font> render our <font color="blue">product <font color="blue">candidates</font></font> or <font color="blue">technologies</font>     obsolete  or <font color="blue">noncompetitive</font></td>
    </tr>
    <tr>
      <td>We face and <font color="blue">will continue</font> to <font color="blue">face intense</font>     <font color="blue">competition</font>  from  other companies for <font color="blue">collaborative</font> <font color="blue">arrangement</font>s with     <font color="blue">pharmaceutical</font> and bio<font color="blue">technology</font> companies, for <font color="blue">establishing</font> relationships     with academic and <font color="blue">research institutions</font>, and for licenses of products or     <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>These <font color="blue"><font color="blue">competitor</font>s</font>, either alone or with their <font color="blue">collaborative</font>     partners, may succeed in developing <font color="blue">technologies</font> or products that are more     <font color="blue"><font color="blue">effective</font> than</font> ours</td>
    </tr>
    <tr>
      <td>25       _________________________________________________________________    [76]Table of <font color="blue">Contents       </font>If we experience delays in obtaining <font color="blue"><font color="blue"><font color="blue">regulatory</font> approval</font>s</font>, or are unable to     obtain or maintain <font color="blue"><font color="blue"><font color="blue">regulatory</font> approval</font>s</font>, we may be unable to <font color="blue">commercialize</font>     any products</td>
    </tr>
    <tr>
      <td>Our  <font color="blue">product <font color="blue">candidates</font></font> are subject to extensive and <font color="blue">rigorous domestic</font>     <font color="blue">government</font>  regulation</td>
    </tr>
    <tr>
      <td>The  FDA  regulates,  among other things, the     <font color="blue">development</font>,  testing,  <font color="blue">manufacture</font>, safety, efficacy, record-keeping,     labeling, storage, approval, advertising, promotion, sale and <font color="blue">distribution</font>     of <font color="blue">pharmaceutical</font> products</td>
    </tr>
    <tr>
      <td>If our products are <font color="blue">marketed abroad</font>, they will     also be subject to extensive regulation by foreign <font color="blue">government</font>s</td>
    </tr>
    <tr>
      <td>None of our     PULSYS <font color="blue">product <font color="blue">candidates</font></font> has <font color="blue">been approved</font> for sale in the US or any     <font color="blue">foreign market</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">regulatory</font> review and <font color="blue">approval process</font> takes many years,     requires the <font color="blue">expenditure</font> of substantial resources, involves post-marketing     surveillance  and  may involve ongoing <font color="blue">requirements</font> for post-marketing     studies</td>
    </tr>
    <tr>
      <td>The  actual time required for <font color="blue">satisfaction</font> of FDA pre-market     approval <font color="blue">requirements</font> may vary <font color="blue">substantially</font> based upon the type, <font color="blue">complexity</font>     and novelty of the product or the <font color="blue">medical condition</font> it is intended to treat</td>
    </tr>
    <tr>
      <td><font color="blue">Government </font><font color="blue">regulation may delay</font> or <font color="blue">prevent marketing</font> of <font color="blue">potential products</font>     for  a considerable period of time and <font color="blue">impose costly procedures upon</font> a     <font color="blue">manufacture</font>r’s <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>Delays in obtaining <font color="blue"><font color="blue"><font color="blue">regulatory</font> approval</font>s</font> may:         •  <font color="blue">adversely</font> affect the <font color="blue">commercialization</font> of any drugs that we or our     <font color="blue"><font color="blue">collaborative</font> partners</font> develop;         •  <font color="blue">impose costly procedures on us</font> or our <font color="blue"><font color="blue">collaborative</font> partners</font>;          •  diminish any <font color="blue">competitive advantage</font>s that we or our <font color="blue">collaborative</font>     <font color="blue">partners may</font> attain; and         •  <font color="blue">adversely</font> affect our receipt of revenues or royalties</td>
    </tr>
    <tr>
      <td>Data obtained from clinical <font color="blue">activities</font> is not always     <font color="blue">conclusive</font> and may be susceptible to <font color="blue">varying interpretations</font> that could     delay, limit or prevent <font color="blue"><font color="blue">regulatory</font> approval</font></td>
    </tr>
    <tr>
      <td>Any required approvals, once obtained, may be withdrawn</td>
    </tr>
    <tr>
      <td>Further, if we fail     to <font color="blue"><font color="blue">comply with</font> applicable</font> FDA and other <font color="blue">regulatory</font> <font color="blue">requirements</font> at any stage     during the <font color="blue">regulatory</font> process, we <font color="blue">may encounter <font color="blue">difficult</font>ies</font> including:         •  delays in <font color="blue"><font color="blue">clinical trial</font>s</font> or <font color="blue">commercialization</font>;         •  <font color="blue">product recalls</font> or seizures;         •  suspension of production and/or <font color="blue">distribution</font>;         •  <font color="blue">withdrawals</font> of <font color="blue">previously</font> approved marketing <font color="blue"><font color="blue">application</font>s</font>; and         •  fines, civil penalties and <font color="blue">criminal prosecutions</font></td>
    </tr>
    <tr>
      <td>We may rely on future <font color="blue"><font color="blue">collaborative</font> partners</font> to file <font color="blue">investigation</font>al new     drug <font color="blue"><font color="blue">application</font>s</font> and <font color="blue">generally direct</font> the <font color="blue"><font color="blue">regulatory</font> approval</font> process for     many  of our products</td>
    </tr>
    <tr>
      <td>These <font color="blue"><font color="blue">collaborative</font> partners</font> may not be able to     <font color="blue">conduct clinical testing</font> or obtain <font color="blue">necessary</font> approvals from the FDA or other     <font color="blue">regulatory</font> <font color="blue">authorities</font> for any <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>If we fail to obtain     required <font color="blue">government</font>al approvals, we or our <font color="blue"><font color="blue">collaborative</font> partners</font> will     experience delays in, or be precluded from, <font color="blue">marketing products</font> developed     through our research</td>
    </tr>
    <tr>
      <td>We  and  our  contract  <font color="blue">manufacture</font>rs also are required to <font color="blue">comply with</font>     applicable FDA good <font color="blue">manufacturing</font> <font color="blue">practice <font color="blue">regulations</font></font></td>
    </tr>
    <tr>
      <td>Good <font color="blue">manufacturing</font>     <font color="blue">practice <font color="blue">regulations</font></font> include <font color="blue">requirements</font> relating to <font color="blue">quality control</font> and     <font color="blue">quality assurance as well as</font> the <font color="blue">corresponding</font> maintenance of records and     <font color="blue">documentation</font></td>
    </tr>
    <tr>
      <td><font color="blue">Manufacturing </font><font color="blue">facilities</font> are subject to <font color="blue">inspection by</font> the     FDA These <font color="blue">facilities</font> must be approved before we can use them in commercial     <font color="blue">manufacturing</font> of our products</td>
    </tr>
    <tr>
      <td>We or our contract <font color="blue">manufacture</font>rs may not be     able to <font color="blue">comply with</font> the applicable good <font color="blue">manufacturing</font> practice <font color="blue">requirements</font>     <font color="blue">and other FDA </font><font color="blue">regulatory</font> <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>If we or our contract <font color="blue">manufacture</font>rs     fail to comply, we could be subject to fines or other sanctions, or be     <font color="blue">precluded from marketing</font> our products</td>
    </tr>
    <tr>
      <td>26       _________________________________________________________________    [77]Table of <font color="blue">Contents       </font>The <font color="blue">manufacture</font> and storage of <font color="blue">pharmaceutical</font> and <font color="blue">chemical products</font> is     subject to <font color="blue"><font color="blue">environmental</font> regulation</font> and risk</td>
    </tr>
    <tr>
      <td>Because of the <font color="blue">chemical ingredients</font> of <font color="blue">pharmaceutical</font> products and the     nature  of their <font color="blue">manufacturing</font> process, the <font color="blue">pharmaceutical</font> industry is     subject to extensive <font color="blue"><font color="blue">environmental</font> regulation</font> and the risk of incurring     <font color="blue">liability</font> for damages or the costs of <font color="blue">remedying <font color="blue">environmental</font> problems</font></td>
    </tr>
    <tr>
      <td>We     use a number of <font color="blue">chemicals</font> and <font color="blue">drug substances</font> that can be toxic to humans</td>
    </tr>
    <tr>
      <td>These <font color="blue">chemicals</font> include acids, solvents and other <font color="blue">reagents used</font> in the     normal  course  of our chemical and <font color="blue">pharmaceutical</font> analysis, and other     materials, such as polymers, <font color="blue">inactive ingredients</font> and <font color="blue">drug substances</font>, used     in the research, <font color="blue">development</font> and <font color="blue">manufacture</font> of <font color="blue">drug products</font></td>
    </tr>
    <tr>
      <td>If we fail to     comply  with <font color="blue"><font color="blue">environmental</font> regulation</font>s to use, discharge or dispose of     hazardous materials <font color="blue"><font color="blue">appropriate</font>ly</font> or otherwise to <font color="blue">comply with</font> the <font color="blue">conditions</font>     attached to our operating licenses, the <font color="blue">licenses could</font> be revoked and we     could be subject to criminal sanctions and/or substantial <font color="blue">liability</font> or could     be required to suspend or modify our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td><font color="blue">Environmental </font>laws and <font color="blue">regulations</font> can require us to undertake or pay for     <font color="blue">investigation</font>,  clean-up and monitoring of <font color="blue"><font color="blue">environmental</font> contamination</font>     identified  at  properties that we currently own or operate or that we     formerly owned or operated</td>
    </tr>
    <tr>
      <td>Further, they can require us to undertake or pay     for <font color="blue">such actions at offsite locations</font> where we may have <font color="blue">sent hazardous</font>     substances for disposal</td>
    </tr>
    <tr>
      <td>These <font color="blue">obligations</font> are <font color="blue">often imposed without</font> regard     to fault</td>
    </tr>
    <tr>
      <td>In the event we are found to have violated <font color="blue">environmental</font> laws or     <font color="blue">regulations</font>, our reputation will be harmed and we may incur substantial     monetary <font color="blue">liabilities</font></td>
    </tr>
    <tr>
      <td>We currently have <font color="blue">insurance coverage</font> that we believe     is adequate to cover our present <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>However, this <font color="blue">insurance may</font> not     be available or adequate to cover any losses arising from contamination or     injury resulting from our use of <font color="blue">hazardous substances</font></td>
    </tr>
    <tr>
      <td>Market <font color="blue">acceptance</font> of our products will be limited if users of our products     are unable to obtain adequate <font color="blue">reimbursement</font> from third-party payors</td>
    </tr>
    <tr>
      <td>The <font color="blue">commercial success</font> of our <font color="blue">product <font color="blue">candidates</font></font> will depend in part on the     <font color="blue">availability</font> of <font color="blue">reimbursement</font> from third-party payors, including <font color="blue">government</font>     health administrators, managed care providers and <font color="blue">private health insurers</font></td>
    </tr>
    <tr>
      <td>Even if we succeed in bringing any of our <font color="blue">proposed products</font> to market, we     cannot  assure  you that third-party payors will consider our products     cost-<font color="blue">effective</font> or provide <font color="blue">reimbursement</font> in whole or in part for their use</td>
    </tr>
    <tr>
      <td><font color="blue">Significant </font>un<font color="blue">certainty</font> exists as to the <font color="blue">reimbursement</font> status of newly     <font color="blue">approved health care products</font></td>
    </tr>
    <tr>
      <td>Third-party <font color="blue">payors may</font> conclude that our     products are less safe, <font color="blue">effective</font> or cost-<font color="blue"><font color="blue">effective</font> than</font> existing products</td>
    </tr>
    <tr>
      <td>Therefore,  third-party  payors  may  not  approve  our  products  for     <font color="blue">reimbursement</font></td>
    </tr>
    <tr>
      <td>If third-party payors do not approve our products for <font color="blue">reimbursement</font> or fail     to reimburse them adequately, sales will suffer as some physicians or their     <font color="blue">patients will opt</font> for a <font color="blue">competing product</font> that is approved for <font color="blue">reimbursement</font>     or is <font color="blue">adequately reimbursed</font></td>
    </tr>
    <tr>
      <td>Even if third-party payors make <font color="blue">reimbursement</font>     available, <font color="blue">reimbursement</font> levels may not be sufficient for us to realize an     <font color="blue">appropriate</font> return on our <font color="blue">investment</font> in product <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>Moreover, the trend toward managed healthcare in the United States, the     growth  of <font color="blue">organizations</font> such as health maintenance <font color="blue">organizations</font>, and     <font color="blue">legislative</font> proposals to reform healthcare and <font color="blue">government</font> insurance programs     could  <font color="blue">significant</font>ly influence the purchase of healthcare services and     products, resulting in lower prices and reduced demand for our products</td>
    </tr>
    <tr>
      <td>In     addition,   <font color="blue">legislation</font>  and  <font color="blue">regulations</font>  <font color="blue">affecting</font>  the  pricing  of     <font color="blue">pharmaceutical</font>s may change in <font color="blue">ways adverse</font> to us</td>
    </tr>
    <tr>
      <td>While we <font color="blue">cannot predict</font>     the likelihood of any of these <font color="blue">legislative</font> or <font color="blue">regulatory</font> proposals, if any     <font color="blue">government</font>  or  <font color="blue">regulatory</font>  <font color="blue">agencies adopt</font> these proposals, they could     <font color="blue"><font color="blue">materially</font> <font color="blue">adversely</font></font> affect our business, <font color="blue">financial condition</font> and results of     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Other Risks       <font color="blue">HealthCare Ventures </font>V, LP, <font color="blue">HealthCare Ventures </font>VI, LP and HealthCare     Ventures  VII, LP have substantial <font color="blue">control over</font> our business and the     interests of the <font color="blue">HealthCare Ventures </font><font color="blue"><font color="blue">partnerships</font> may</font> not be <font color="blue">consistent with</font>     the interests of our other <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td><font color="blue">HealthCare Ventures </font>V, LP and <font color="blue">HealthCare Ventures </font>VI, LP currently     <font color="blue">beneficially</font> own an aggregate of 36dtta1prca of our <font color="blue">outstanding <font color="blue">common stock</font></font></td>
    </tr>
    <tr>
      <td>James H Cavanaugh and Harold R Werner, members of our board of <font color="blue">directors</font>,     are <font color="blue">general partners</font> of HealthCare Partners V, LP and HealthCare Partners     VI, LP, which are the <font color="blue">general partners</font> of <font color="blue">HealthCare Ventures </font>V, LP and     <font color="blue">HealthCare Ventures </font>VI, LP, <font color="blue">respectively</font></td>
    </tr>
    <tr>
      <td>Accordingly, the                                         27       _________________________________________________________________    [78]Table of <font color="blue">Contents       </font><font color="blue">HealthCare Ventures </font><font color="blue">partnerships</font> are able to exert <font color="blue">significant</font> influence     over all matters requiring <font color="blue">stockholder approval</font>, including the election and     removal  of  <font color="blue">directors</font> and any merger, consolidation or sale of all or     <font color="blue">substantially</font> all of our assets, as well as over the day-to-day <font color="blue">management</font>     of our business</td>
    </tr>
    <tr>
      <td>The <font color="blue">HealthCare Ventures </font><font color="blue"><font color="blue">partnerships</font> may</font> direct our affairs     in  a  manner  that  is not <font color="blue">consistent with</font> the interests of our other     <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>In addition, this <font color="blue">concentration</font> of <font color="blue">ownership could</font> have the     effect of delaying, deferring or preventing a change in control, or impeding     a merger or consolidation, takeover or other business <font color="blue">combination</font> or a sale     of all or <font color="blue">substantially</font> all of our assets</td>
    </tr>
    <tr>
      <td>Future sales of our <font color="blue">common stock</font>, or the <font color="blue">perception</font> that these sales may     occur, <font color="blue">could depress</font> our stock price</td>
    </tr>
    <tr>
      <td>Sales of substantial amounts of our <font color="blue">common stock</font> in the <font color="blue">public market</font>, or     the <font color="blue">perception</font> in the <font color="blue">public market</font>s that these sales may occur, could cause     the <font color="blue">market price</font> of our <font color="blue">common stock</font> to decline</td>
    </tr>
    <tr>
      <td>This <font color="blue">could also impair</font> our ability to raise <font color="blue">additional</font> capital through the     sale of our <font color="blue">equity securities</font></td>
    </tr>
    <tr>
      <td>Selling of a large number of <font color="blue">shares by</font> any of     our <font color="blue">existing shareholders</font> or <font color="blue">management</font> shareholders could cause the price     of our <font color="blue">common stock</font> to decline</td>
    </tr>
    <tr>
      <td>Furthermore, if we file a <font color="blue">registration</font>     statement to offer <font color="blue">additional</font> shares of our <font color="blue">common stock</font> and have to include     shares held by those holders, it <font color="blue">could impair</font> our ability to raise needed     <font color="blue">capital by depressing</font> the <font color="blue">price at which</font> we <font color="blue">could sell</font> our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Our  <font color="blue">certificate</font> of <font color="blue">incorporation</font> and provisions of <font color="blue">Delaware </font>law could     discourage a takeover you may consider favorable or could cause current     <font color="blue">management</font> to <font color="blue">become entrenched</font> and <font color="blue">difficult</font> to replace</td>
    </tr>
    <tr>
      <td><font color="blue">Provisions </font>in our <font color="blue">certificate</font> of <font color="blue">incorporation</font> and <font color="blue">Delaware </font>law may have the     effect of delaying or preventing a merger or <font color="blue">acquisition</font> of us, or making a     merger or <font color="blue">acquisition</font> less desirable to a potential acquirer, even when the     <font color="blue">stockholders</font> may consider the <font color="blue">acquisition</font> or merger favorable</td>
    </tr>
    <tr>
      <td>Under the     terms  of our <font color="blue">certificate</font> of <font color="blue">incorporation</font>, we are authorized to issue     25 million shares of “blank check” preferred stock, and to determine the     price, privileges, and other terms of these shares</td>
    </tr>
    <tr>
      <td>The issuance of any     <font color="blue">preferred stock with</font> superior rights to our <font color="blue">common stock</font> could reduce the     value of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>In particular, specific rights we may grant to     <font color="blue">future holders</font> of <font color="blue">preferred stock could</font> be used to restrict an ability to     merge  with or sell our assets to a <font color="blue">third party</font>, preserving control by     <font color="blue">present owners</font> and <font color="blue">management</font> and preventing you from realizing a <font color="blue">premium on</font>     your shares</td>
    </tr>
    <tr>
      <td>In addition, we are subject to provisions of the <font color="blue">Delaware </font><font color="blue">corporation law</font>     that, in general, prohibit any business <font color="blue">combination</font> with a <font color="blue">beneficial owner</font>     of  15prca or more of our <font color="blue">common stock</font> for <font color="blue">five years unless</font> the holder’s     <font color="blue">acquisition</font> of our stock was approved in <font color="blue">advance by</font> our board of <font color="blue">directors</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">provisions could affect</font> our stock price <font color="blue">adversely</font></td>
    </tr>
    <tr>
      <td>The  price of our <font color="blue">common stock</font> has been and <font color="blue">will likely continue</font> to be     volatile</td>
    </tr>
    <tr>
      <td><font color="blue">Prior to October </font>2003, there was no <font color="blue">public market</font> for our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>We     cannot  predict the extent to <font color="blue">which investor interest will lead</font> to the     <font color="blue">development</font> of an active and <font color="blue">liquid trading market</font> in our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>The     <font color="blue"><font color="blue">initial public offering</font> price</font> of our <font color="blue">common stock</font> was dlra10dtta00 per share</td>
    </tr>
    <tr>
      <td>Since our <font color="blue">initial public offering</font>, the price of our <font color="blue">common stock</font> has been as     high as dlra10dtta30 and as low as dlra0dtta86 per share</td>
    </tr>
    <tr>
      <td>Some companies that have had     volatile <font color="blue">market price</font>s for their securities have been subject to securities     class <font color="blue">action suits filed against them</font></td>
    </tr>
    <tr>
      <td>If a suit were to be filed against     us, <font color="blue">regardless</font> of the outcome, it could result in substantial costs and a     diversion of our <font color="blue">management</font>’s attention and resources</td>
    </tr>
    <tr>
      <td>This could have a     material adverse effect on our business, results of <font color="blue">operations</font> and financial     condition</td>
    </tr>
    <tr>
      <td>We could be forced to <font color="blue">pay liquidated damages</font> if we do not maintain the     <font color="blue">effective</font>ness of our S-3 <font color="blue">registration</font> statement</td>
    </tr>
    <tr>
      <td>In April 2005, we completed a <font color="blue">private placement</font> of 6cmam846cmam735 shares of our     <font color="blue">common stock</font> at a price of dlra3dtta98 per share and warrants to purchase a total     of 2cmam396cmam357 shares of <font color="blue">common stock</font> at an <font color="blue">exercise price</font> of dlra4dtta78 per share,     resulting in gross proceeds of dlra27dtta25 million</td>
    </tr>
    <tr>
      <td>Pursuant to the terms of the     <font color="blue">registration</font>  rights  <font color="blue">agreement</font>,  we <font color="blue">filed with</font> the SEC a <font color="blue">registration</font>     statement on Form S-3 covering the resale of <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">registration</font>     rights <font color="blue">agreement</font> provides that if a <font color="blue">registration</font> statement is not <font color="blue">effective</font>     within 60 days of closing, or if we do not                                         28       _________________________________________________________________    [79]Table of <font color="blue">Contents       </font><font color="blue">subsequently</font> maintain the <font color="blue">effective</font>ness of the <font color="blue">registration</font> statement, then     in addition to any other rights the <font color="blue">investor may</font> have, we will be required     to pay the <font color="blue">investor liquidated damages</font>, in cash, equal to <font color="blue">one percent per</font>     month of the <font color="blue">aggregate purchase price paid by such investor</font></td>
    </tr>
    <tr>
      <td>The SEC declared our Form S-3 <font color="blue">effective</font> on June 1, 2005, which was within     60 days  of  closing</td>
    </tr>
    <tr>
      <td>We believe that the events that would lead to a     suspension of <font color="blue">effective</font>ness are unlikely to occur</td>
    </tr>
    <tr>
      <td>However, if we fail to     maintain the <font color="blue">effective</font>ness of the <font color="blue">registration</font> statement in the future,     <font color="blue">liquidated damages could</font> be substantial</td>
    </tr>
  </tbody>
</table>